• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Cellectis Inc.

    < Previous 1 2 Next >
    Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024
    From Cellectis Inc.
    Via GlobeNewswire
    Tickers CLLS
    Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress
    From Cellectis Inc.
    Via GlobeNewswire
    Tickers CLLS
    Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety
    From Cellectis Inc.
    Via GlobeNewswire
    Tickers CLLS
    Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors
    From Cellectis Inc.
    Via GlobeNewswire
    Tickers CLLS
    Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer
    From Cellectis Inc.
    Via GlobeNewswire
    Tickers CLLS
    Cellectis Provides Financial Results for the Second Quarter 2024
    From Cellectis Inc.
    Via GlobeNewswire
    Tickers CLLS
    FDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL Treatment
    From Cellectis Inc.
    Via GlobeNewswire
    Tickers CLLS
    FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment
    From Cellectis Inc.
    Via GlobeNewswire
    Tickers CLLS
    Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024
    From Cellectis Inc.
    Via GlobeNewswire
    Tickers CLLS
    Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing
    From Cellectis Inc.
    Via GlobeNewswire
    Tickers CLLS
    Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications
    From Cellectis Inc.
    Via GlobeNewswire
    Tickers CLLS
    Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia
    From Cellectis Inc.
    Via GlobeNewswire
    Tickers CLLS
    Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024
    From Cellectis Inc.
    Via GlobeNewswire
    Tickers CLLS
    Cellectis Reports Financial Results for First Quarter 2024
    From Cellectis Inc.
    Via GlobeNewswire
    Tickers AZN CLLS
    Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024
    From Cellectis Inc.
    Via GlobeNewswire
    Tickers CLLS
    Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
    From Cellectis Inc.
    Via GlobeNewswire
    Tickers AZN CLLS
    Cellectis Appoints Arthur Stril as Interim Chief Financial Officer
    From Cellectis Inc.
    Via GlobeNewswire
    Tickers CLLS
    Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023
    From Cellectis Inc.
    Via GlobeNewswire
    Tickers CLLS
    Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs
    From Cellectis Inc.
    Via GlobeNewswire
    Tickers CLLS
    Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs
    From Cellectis Inc.
    Via GlobeNewswire
    Tickers CLLS
    Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting
    From Cellectis Inc.
    Via GlobeNewswire
    Tickers CLLS
    Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)
    From Cellectis Inc.
    Via GlobeNewswire
    Tickers CLLS
    Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023
    From Cellectis Inc.
    Via GlobeNewswire
    Tickers CLLS
    Cellectis’ Shareholders Meeting to be Held on December 22, 2023
    From Cellectis Inc.
    Via GlobeNewswire
    Tickers CLLS
    Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca
    From Cellectis Inc.
    Via GlobeNewswire
    Tickers CLLS
    Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023
    From Cellectis Inc.
    Via GlobeNewswire
    Tickers CLLS
    Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual Meeting
    From Cellectis Inc.
    Via GlobeNewswire
    Tickers CLLS
    Cellectis to Report Third Quarter 2023 Financial Results on November 6, 2023
    From Cellectis Inc.
    Via GlobeNewswire
    Tickers CLLS
    Cellectis Announces Strategic Collaboration and Investment Agreements with AstraZeneca
    From Cellectis Inc.
    Via GlobeNewswire
    Tickers CLLS
    Cellectis Presents Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
    From Cellectis Inc.
    Via GlobeNewswire
    Tickers CLLS
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.